{"id":"W3016349309","doi":"10.1002/cncr.32883","title":"Pembrolizumab for the treatment of programmed death–ligand 1‒positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE‐028 study","year":2020,"lang":"en","type":"article","venue":"Cancer","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":150,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Pharmacyclics; Chugai Pharmaceutical; Merck Sharp and Dohme; EMD Serono; Genentech; Bavarian Nordic; Sirtex Medical; FibroGen; Eisai; Celgene; Rakuten Medical; Aminex Therapeutics; Pfizer; Incyte; Ipsen; Five Prime Therapeutics; Les Laboratories Pierre Fabre; MacroGenics; Celldex Therapeutics; Principia Biopharma; Puma Biotechnology; National Institutes of Health; Regeneron Pharmaceuticals; BioMarin Pharmaceutical; Daiichi Sankyo Europe; National Cancer Institute; Servier; Gilead Sciences; Alexion Pharmaceuticals; Halozyme; Kyowa Hakko Kirin; Sanofi; GlaxoSmithKline; Amgen; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Pembrolizumab; Cohort; Internal medicine; Neuroendocrine tumors; Clinical endpoint; Gastroenterology; Response Evaluation Criteria in Solid Tumors; Oncology; Progressive disease; Immunotherapy; Cancer; Disease; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004450824,0.0006893747,0.001038855,0.0001926855,0.0002269605,0.0009088936,0.0004534476,0.0007907351,0.001871624],"category_scores_gemma":[0.001930774,0.0001985621,0.001511996,0.0003341005,0.000280971,0.0006542936,0.0003686791,0.001329879,0.0003941576],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005916051,"about_ca_system_score_gemma":0.0007974211,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005566977,"about_ca_topic_score_gemma":0.001163948,"domain_scores_codex":[0.9991399,0.000477618,0.00006845494,0.00009506167,0.0001262217,0.00009259348],"domain_scores_gemma":[0.9986777,0.0003676981,0.0003859036,0.000101937,0.0001464008,0.0003204209],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5625326,0.01205185,0.04687714,0.004672956,0.01039274,0.0004444612,0.0004460238,0.003569223,0.01890996,0.0005590548,0.02343498,0.316109],"study_design_scores_gemma":[0.4804661,0.2025156,0.2457676,0.001342559,0.01499716,0.001259078,0.0002894722,0.002566215,0.005223996,0.0007322701,0.04472695,0.0001129029],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9409725,0.04406526,0.0008152648,0.001723056,0.0002364693,0.001303604,0.005529025,0.00006035769,0.005294547],"genre_scores_gemma":[0.9713979,0.01366877,0.0009429167,0.002222183,0.0003276295,0.001091587,0.008681488,0.000025159,0.001642213],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004450824,"threshold_uncertainty_score":0.02353853,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07047732118771373,"score_gpt":0.3677005988134592,"score_spread":0.2972232776257455,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}